Nourianz and Ombitasvir, paritaprevir, ritonavir and dasabuvir
Determining the interaction of Nourianz and Ombitasvir, paritaprevir, ritonavir and dasabuvir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. In study subjects, administration of a single 40 mg dose of istradefylline with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 4 days) increased the total systemic exposure (AUC(inf)) of istradefylline by 2.5-fold. MANAGEMENT: The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia. References "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.
Professional:ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. In study subjects, administration of a single 40 mg dose of istradefylline with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 4 days) increased the total systemic exposure (AUC(inf)) of istradefylline by 2.5-fold.
MANAGEMENT: The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.
- "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Nourianz-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
- Nourianz-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Nourianz-Omeclamox-Pak
- Nourianz-Omega-3 Fatty Acid Capsules
- Nourianz-Omega-3 Fatty Acids
- Nourianz-Omega-3 polyunsaturated fatty acids
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Nov-Onxol
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Novacort
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Novaferrum
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-NovaFerrum 50
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-NovaFerrum Pediatric Drops
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-NovaFerrum Pediatric Multivitamins with Iron